Abstract
Retinoids have demonstrated activity in the prevention of second primary tumors in patients with non-small cell lung cancer (NSCLC). They also contribute to the normal growth and differentiation of human bronchial epithelial (HBE) cells. Because retinoids mediate their actions through retinoid nuclear receptors (RARs and RXRs), aberrant signaling through retinoid receptors could contribute to lung carcinogenesis. Using a lung carcinogenesis model consisting of normal, premalignant, and malignant HBE cells, we examined all-trans retinoic acid (t-RA)-induced changes in cellular growth. These studies revealed that t-RA treatment inhibited the growth of normal HBE cells, but premalignant and malignant HBE cells were relatively resistant to t-RA. Coincident with the development of retinoid refractoriness, basal expression of the retinoic acid nuclear receptor β (RAR-β) increased. Analysis of receptor function by gel shift and transient transfection assays of normal, premalignant, and malignant HBE cells demonstrated that receptor-DNA binding and transcriptional activation properties were intact in the t-RA-refractory malignant HBE cells. To compare these findings to NSCLCs in patients, we investigated retinoid receptor expression in NSULC biopsies. A subset of the tumors expressed RAR-β, reflecting the RAR-β expression observed in the malignant HBE cells in culture. These findings demonstrate that retinoid receptor function was intact in the t-RA-refractory malignant HBE cell line, suggesting that the defect in retinoid signaling in this lung carcinogenesis model is not intrinsic to the retinoid receptors.
| Original language | English |
|---|---|
| Pages (from-to) | 5603-5610 |
| Number of pages | 8 |
| Journal | Cancer Research |
| Volume | 55 |
| Issue number | 23 |
| Publication status | Published - 1995 Jan 1 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors. / Kim, Yeul Hong; Dohi, D. F.; Gil Ro Han, Ro Han; Zou, C. P.; Oridate, N.; Walsh, G. L.; Nesbitt, J. C.; Xu, X. C.; Waun Ki Hong, Ki Hong; Lotan, R.; Kurie, J. M.
In: Cancer Research, Vol. 55, No. 23, 01.01.1995, p. 5603-5610.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Retinoid refractoriness occurs during lung carcinogenesis despite functional retinoid receptors
AU - Kim, Yeul Hong
AU - Dohi, D. F.
AU - Gil Ro Han, Ro Han
AU - Zou, C. P.
AU - Oridate, N.
AU - Walsh, G. L.
AU - Nesbitt, J. C.
AU - Xu, X. C.
AU - Waun Ki Hong, Ki Hong
AU - Lotan, R.
AU - Kurie, J. M.
PY - 1995/1/1
Y1 - 1995/1/1
N2 - Retinoids have demonstrated activity in the prevention of second primary tumors in patients with non-small cell lung cancer (NSCLC). They also contribute to the normal growth and differentiation of human bronchial epithelial (HBE) cells. Because retinoids mediate their actions through retinoid nuclear receptors (RARs and RXRs), aberrant signaling through retinoid receptors could contribute to lung carcinogenesis. Using a lung carcinogenesis model consisting of normal, premalignant, and malignant HBE cells, we examined all-trans retinoic acid (t-RA)-induced changes in cellular growth. These studies revealed that t-RA treatment inhibited the growth of normal HBE cells, but premalignant and malignant HBE cells were relatively resistant to t-RA. Coincident with the development of retinoid refractoriness, basal expression of the retinoic acid nuclear receptor β (RAR-β) increased. Analysis of receptor function by gel shift and transient transfection assays of normal, premalignant, and malignant HBE cells demonstrated that receptor-DNA binding and transcriptional activation properties were intact in the t-RA-refractory malignant HBE cells. To compare these findings to NSCLCs in patients, we investigated retinoid receptor expression in NSULC biopsies. A subset of the tumors expressed RAR-β, reflecting the RAR-β expression observed in the malignant HBE cells in culture. These findings demonstrate that retinoid receptor function was intact in the t-RA-refractory malignant HBE cell line, suggesting that the defect in retinoid signaling in this lung carcinogenesis model is not intrinsic to the retinoid receptors.
AB - Retinoids have demonstrated activity in the prevention of second primary tumors in patients with non-small cell lung cancer (NSCLC). They also contribute to the normal growth and differentiation of human bronchial epithelial (HBE) cells. Because retinoids mediate their actions through retinoid nuclear receptors (RARs and RXRs), aberrant signaling through retinoid receptors could contribute to lung carcinogenesis. Using a lung carcinogenesis model consisting of normal, premalignant, and malignant HBE cells, we examined all-trans retinoic acid (t-RA)-induced changes in cellular growth. These studies revealed that t-RA treatment inhibited the growth of normal HBE cells, but premalignant and malignant HBE cells were relatively resistant to t-RA. Coincident with the development of retinoid refractoriness, basal expression of the retinoic acid nuclear receptor β (RAR-β) increased. Analysis of receptor function by gel shift and transient transfection assays of normal, premalignant, and malignant HBE cells demonstrated that receptor-DNA binding and transcriptional activation properties were intact in the t-RA-refractory malignant HBE cells. To compare these findings to NSCLCs in patients, we investigated retinoid receptor expression in NSULC biopsies. A subset of the tumors expressed RAR-β, reflecting the RAR-β expression observed in the malignant HBE cells in culture. These findings demonstrate that retinoid receptor function was intact in the t-RA-refractory malignant HBE cell line, suggesting that the defect in retinoid signaling in this lung carcinogenesis model is not intrinsic to the retinoid receptors.
UR - http://www.scopus.com/inward/record.url?scp=0028883558&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028883558&partnerID=8YFLogxK
M3 - Article
C2 - 7585641
AN - SCOPUS:0028883558
VL - 55
SP - 5603
EP - 5610
JO - Cancer Research
JF - Cancer Research
SN - 0008-5472
IS - 23
ER -